FCER2 and mantle cell lymphoma: Three attractive targets, CD23 (present on CLL cells) (95), ROR1 (present on CLL and MCL) (96), and immunoglobulin kappa (κ) light chain (present on MCL, DLBCL, and some other NHLs) (97) are being evaluated for their anticancer activity in preclinical models since they are either not expressed or present at low levels in normal cells.